Earnings Report /

Rameda Pharmaceuticals: Covid-related antivirals support sales growth but pressure margins

  • Retail market continues to slowly recover in 1Q21

  • New launches’ sales and covid related antivirals drive topline growth

  • Higher covid-related antivirals’ initial APIs costs pressure operating margins


Tellimer | Start Following

Start following your markets today

Follow your key analysts, markets and more so they appear here in your Watchlist - allowing you to keep an eye on the latest updates.